Site-Specific Mutations in the 23S rRNA Gene of Helicobacter pylori Confer Two Types of Resistance to Macrolide-Lincosamide-Streptogramin B Antibiotics
- 1 August 1998
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 42 (8), 1952-1958
- https://doi.org/10.1128/aac.42.8.1952
Abstract
Clarithromycin resistance in Helicobacter pylori is mainly due to A-to-G mutations within the peptidyltransferase region of the 23S rRNA. In the present study, cross-resistance to macrolide, lincosamide, and streptogramin B (MLS) antibiotics (MLS phenotypes) has been investigated for several clinical isolates of H. pylori. Two major types of MLS resistance were identified and correlated with specific point mutations in the 23S rRNA gene. The A2142G mutation was linked with high-level cross-resistance to all MLS antibiotics (type I), and the A2143G mutation gave rise to an intermediate level of resistance to clarithromycin and clindamycin but no resistance to streptogramin B (type II). In addition, streptogramin A and streptogramin B were demonstrated to have a synergistic effect on both MLS-sensitive and MLS-resistant H. pyloristrains. To further understand the mechanism of MLS resistance inH. pylori, we performed in vitro site-directed mutagenesis (substitution of G, C, or T for A at either position 2142 or 2143 of the 23S rRNA gene). The site-directed point mutations were introduced into a clarithromycin-susceptible strain, H. pylori UA802, by natural transformation followed by characterization of their effects on MLS resistance in an isogenic background. Strains with A-to-G and A-to-C mutations at the same position within the 23S rRNA gene had similar levels of clarithromycin resistance, and this level of resistance was higher than that for strains with the A-to-T mutation. Mutations at position 2142 conferred a higher level of clarithromycin resistance than mutations at position 2143. All mutations at position 2142 conferred cross-resistance to all MLS antibiotics, which corresponds to the type I MLS phenotype, whereas mutations at position 2143 were associated with a type II MLS phenotype with no resistance to streptogramin B. To explain that A-to-G transitions were predominantly observed in clarithromycin-resistant clinical isolates, we propose a possible mechanism by which A-to-G mutations are preferentially produced in H. pylori.Keywords
This publication has 41 references indexed in Scilit:
- Cloning and Heterologous Expression of an α1,3-Fucosyltransferase Gene from the Gastric PathogenHelicobacter pyloriJournal of Biological Chemistry, 1997
- Identification of a 23S rRNA Gene Mutation in Clarithromycin‐Resistant Helicobacter pyloriHelicobacter, 1996
- Quinupristin-DalfopristinDrugs, 1996
- Mechanism of clarithromycin resistance in clinical isolates ofHelicobacter pyloriFEMS Microbiology Letters, 1996
- Variability of gene order in different Helicobacter pylori strains contributes to genome diversityMolecular Microbiology, 1996
- Antimicrobial resistance and Helicobacter pyloriJournal of Antimicrobial Chemotherapy, 1996
- Peptic ulcer disease and Helicobacter pylori infectionCurrent Opinion in Gastroenterology, 1994
- Helicobacter pyloriInfection and the Risk of Gastric CarcinomaNew England Journal of Medicine, 1991
- Chloramphenicol, erythromycin, carbomycin and vernamycin B protect overlapping sites in the peptidyl transferase region of 23S ribosomal RNABiochimie, 1987
- A plasmid-coded and site-directed mutation in Escherichia coli 23S RNA that confers resistance to erythromycin: implications for the mechanism of action of erythromycinBiochimie, 1987